

Cambridge, Massachusetts-based Catamaran Bio, Inc, a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, has raised $42 million in financing. Sofinnova Partners and Lightstone Ventures led the round.
Source: Press Release